Search

Displaying results 7641 - 7650 of 10000 in total
  1. Drug

    Milpecitinib

    go.drugbank.com/drugs/DB21676
    Experimental

    Milpecitinib is a small molecule drug. Milpecitinib has a monoisotopic molecular weight of 380.13 Da.

  2. Drug

    Claziprotamide

    go.drugbank.com/drugs/DB21687
    Experimental

    Claziprotamide is a small molecule drug. Claziprotamide has a monoisotopic molecular weight of 374.13 Da.

  3. Drug

    N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide

    go.drugbank.com/drugs/DB08559
    Experimental

    This drug is known to target penicillin G acylase. … N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide is a solid. This compound belongs to the penicillins.

    Synonyms: N-[(2S,4S,6R)-2-(dihydroxymethyl)-4-hydroxy-3,3-dimethyl-7-oxo-4lambda~4~-thia-1-azabicyclo[3.2.0]hept-6-yl]-2-phenylacetamide
  4. Drug

    Reloxiliase

    go.drugbank.com/drugs/DB17653
    Experimental

    Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.[A258823]

  5. Drug

    AGA2115

    go.drugbank.com/drugs/DB17840
    Investigational

    AGA2115 is a humanized bispecific antibody neutralizing both sclerostin and Dickkopf-1. … Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.[L46646]

  6. Drug

    ALT-P1

    go.drugbank.com/drugs/DB18485
    Investigational

    ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.

  7. Drug

    GLPG-1205

    go.drugbank.com/drugs/DB15346
    Investigational

    GLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)).

    Categories: Heterocyclic Compounds, 2-Ring
  8. Drug

    Pelitinib

    go.drugbank.com/drugs/DB05524
    Investigational

    Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.

    Categories: Heterocyclic Compounds, 2-RingSynonyms: (2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide
  9. Drug

    XT-150

    go.drugbank.com/drugs/DB21756
    Investigational

    XT-150 is a locally injectable non-viral therapy expressing IL-10v, a proprietary modified variant of IL-10.[L52125] It is being developed by Xalud Therapeutics.

  10. Drug

    RD13-02

    go.drugbank.com/drugs/DB27110
    Investigational

    RD13-02 is a biologic drug. RD13-02 is under investigation in clinical trial NCT05923541 (RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies).